NCT03261401: First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants
- State
- Completed
- Phase
- Phase 1
- People
- 88 taking part
- Started
- 15 Sep 2017
- Primary completion
- 14 Jun 2019
- Arms
- Part A: Cohort 1 SAD: M5717 50 mg, Part A: Cohort 2 SAD: M5717 100 mg, Part A: Cohort 3 SAD: M5717 200 mg, Part A: Cohort 4 SAD: M5717 400 mg, Part A: Cohort 5 SAD: M5717 600 mg, Part A: Cohort 6 SAD: M5717 1000 mg, Part A: Cohort 7 SAD: M5717 1250 mg, Part A: Cohort 8 SAD: M5717 1800 mg, Part A: Cohort 9 SAD: M5717 2100 mg, Part C: Challenge Cohort 2 M5717 150 mg, Part C: Challenge Cohort 1 M5717 400 mg, Part C: Challenge Cohort 3 M5717 800 mg
- Results
- Posted on the registry
- Papers
- doi:10.1016/s1473-3099(21)00252-8
- 25 Aug 2017: Trial registered
- 15 Sep 2017: Trial started
- 14 Jun 2019: Trial completed
- 16 Oct 2023: Trial results posted